Bavarian Nordic A/S (BAVA.CO)
DKK 198.95
(2.82%)
DKK 198.95
(2.82%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.52 Billion DKK | 165.79% |
| 2022 | 1.7 Billion DKK | 198.3% |
| 2021 | 570.31 Million DKK | -13.23% |
| 2020 | 657.28 Million DKK | 113.59% |
| 2019 | 307.73 Million DKK | 25.35% |
| 2018 | 245.5 Million DKK | -77.26% |
| 2017 | 1.07 Billion DKK | 52.27% |
| 2016 | 708.94 Million DKK | 17.1% |
| 2015 | 605.42 Million DKK | -16.12% |
| 2014 | 721.73 Million DKK | -0.83% |
| 2013 | 727.79 Million DKK | 44.67% |
| 2012 | 503.08 Million DKK | 318.49% |
| 2011 | 120.21 Million DKK | 192.19% |
| 2010 | -130.39 Million DKK | -99.64% |
| 2009 | -65.31 Million DKK | -637.79% |
| 2008 | 12.14 Million DKK | -95.62% |
| 2007 | 276.98 Million DKK | 329.47% |
| 2006 | 64.49 Million DKK | -44.1% |
| 2005 | 115.37 Million DKK | 22.04% |
| 2004 | 94.53 Million DKK | -70.22% |
| 2003 | 317.45 Million DKK | 391.24% |
| 2002 | 64.62 Million DKK | 0.0% |
| 2001 | - DKK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 719.95 Million DKK | 171.44% |
| 2024 Q1 | 265.23 Million DKK | -83.59% |
| 2023 Q2 | 1.3 Billion DKK | 58.18% |
| 2023 FY | 4.52 Billion DKK | 165.79% |
| 2023 Q3 | 862.03 Million DKK | -33.84% |
| 2023 Q4 | 1.61 Billion DKK | 87.54% |
| 2023 Q1 | 823.65 Million DKK | -13.13% |
| 2022 FY | 1.7 Billion DKK | 198.3% |
| 2022 Q3 | 619.81 Million DKK | 488.14% |
| 2022 Q1 | 27.87 Million DKK | -82.24% |
| 2022 Q2 | 105.38 Million DKK | 278.09% |
| 2022 Q4 | 948.19 Million DKK | 52.98% |
| 2021 FY | 570.31 Million DKK | -13.23% |
| 2021 Q1 | 157.91 Million DKK | 261.11% |
| 2021 Q2 | 120.69 Million DKK | -23.57% |
| 2021 Q3 | 134.74 Million DKK | 11.64% |
| 2021 Q4 | 156.96 Million DKK | 16.49% |
| 2020 Q2 | 320.08 Million DKK | 161.68% |
| 2020 Q3 | 312.89 Million DKK | -2.25% |
| 2020 Q4 | -98.01 Million DKK | -131.32% |
| 2020 FY | 657.28 Million DKK | 113.59% |
| 2020 Q1 | 122.32 Million DKK | -21.36% |
| 2019 Q1 | 49.27 Million DKK | -30.97% |
| 2019 Q2 | 51.55 Million DKK | 4.62% |
| 2019 Q3 | 51.34 Million DKK | -0.4% |
| 2019 FY | 307.73 Million DKK | 25.35% |
| 2019 Q4 | 155.55 Million DKK | 202.94% |
| 2018 Q2 | 40.68 Million DKK | 620.8% |
| 2018 FY | 245.5 Million DKK | -77.26% |
| 2018 Q1 | -7.81 Million DKK | -129.78% |
| 2018 Q4 | 71.38 Million DKK | -49.46% |
| 2018 Q3 | 141.24 Million DKK | 247.16% |
| 2017 FY | 1.07 Billion DKK | 52.27% |
| 2017 Q3 | 635.53 Million DKK | 135.21% |
| 2017 Q2 | 270.2 Million DKK | 83.11% |
| 2017 Q1 | 147.56 Million DKK | -52.38% |
| 2017 Q4 | 26.23 Million DKK | -95.87% |
| 2016 Q4 | 309.84 Million DKK | 0.86% |
| 2016 Q2 | 88.24 Million DKK | 2310.46% |
| 2016 Q1 | 3.66 Million DKK | -97.53% |
| 2016 FY | 708.94 Million DKK | 17.1% |
| 2016 Q3 | 307.2 Million DKK | 248.11% |
| 2015 FY | 605.42 Million DKK | -16.12% |
| 2015 Q4 | 148.08 Million DKK | 316.46% |
| 2015 Q3 | 35.55 Million DKK | -87.26% |
| 2015 Q2 | 279.1 Million DKK | 95.59% |
| 2015 Q1 | 142.7 Million DKK | -61.87% |
| 2014 Q2 | 79.9 Million DKK | -43.53% |
| 2014 Q4 | 374.23 Million DKK | 196.78% |
| 2014 Q3 | 126.1 Million DKK | 57.82% |
| 2014 FY | 721.73 Million DKK | -0.83% |
| 2014 Q1 | 141.5 Million DKK | -29.11% |
| 2013 Q3 | 183.8 Million DKK | -31.9% |
| 2013 Q4 | 199.59 Million DKK | 8.59% |
| 2013 FY | 727.79 Million DKK | 44.67% |
| 2013 Q1 | 74.5 Million DKK | -43.72% |
| 2013 Q2 | 269.9 Million DKK | 262.28% |
| 2012 FY | 503.08 Million DKK | 318.49% |
| 2012 Q4 | 132.38 Million DKK | -16.58% |
| 2012 Q3 | 158.7 Million DKK | 17.12% |
| 2012 Q2 | 135.5 Million DKK | 77.12% |
| 2012 Q1 | 76.5 Million DKK | -51.98% |
| 2011 Q4 | 159.31 Million DKK | 601.82% |
| 2011 FY | 120.21 Million DKK | 192.19% |
| 2011 Q1 | -26.2 Million DKK | -354.27% |
| 2011 Q2 | -35.6 Million DKK | -35.88% |
| 2011 Q3 | 22.7 Million DKK | 163.76% |
| 2010 Q2 | 12.8 Million DKK | 125.81% |
| 2010 Q1 | -49.6 Million DKK | -800.07% |
| 2010 Q4 | 10.3 Million DKK | 109.92% |
| 2010 FY | -130.39 Million DKK | -99.64% |
| 2010 Q3 | -103.9 Million DKK | -911.72% |
| 2009 Q2 | -39.6 Million DKK | -65.69% |
| 2009 Q1 | -23.9 Million DKK | 0.0% |
| 2009 FY | -65.31 Million DKK | -637.79% |
| 2009 Q4 | 7.08 Million DKK | 179.61% |
| 2009 Q3 | -8.9 Million DKK | 77.53% |
| 2008 FY | 12.14 Million DKK | -95.62% |
| 2007 FY | 276.98 Million DKK | 329.47% |
| 2006 FY | 64.49 Million DKK | -44.1% |
| 2005 FY | 115.37 Million DKK | 22.04% |
| 2004 FY | 94.53 Million DKK | -70.22% |
| 2003 FY | 317.45 Million DKK | 391.24% |
| 2002 FY | 64.62 Million DKK | 0.0% |
| 2001 FY | - DKK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ALK-Abelló A/S | 3.03 Billion DKK | -48.987% |
| Genmab A/S | 16.24 Billion DKK | 72.17% |
| Gubra A/S | 114.93 Million DKK | -3834.149% |
| Novo Nordisk A/S | 196.49 Billion DKK | 97.699% |
| Orphazyme A/S | - DKK | -Infinity% |
| Pharma Equity Group A/S | -480 Thousand DKK | 942131.875% |
| Zealand Pharma A/S | 323.61 Million DKK | -1297.267% |